About PDTi
Prevention, Diagnosis, Treatment Inc. (PDTi) is a U.S. based global health company specializing in vaccines, diagnostics, antivirals, and other innovative tools for effective global distribution. It also promotes biosimilar approval and development to improve the human condition.
PDTi was co-founded by former Centers for Disease Control and Prevention Director, Dr. Robert R. Redfield, M.D., and Dr. Yichen Lu, Ph.D. Working together for over 30 years on vaccine development and HIV/AIDS prevention and treatment strategies, Dr. Lu and Dr. Redfield have designed PDTi to meet the challenge of providing equitable access to human vaccines, diagnostic tools and treatments, in addition to various animal vaccines, to people and countries in need around the world using a unique for-profit business model that will provide scalability and sustainability.
Our Mission
PDTi’s Mission is to create a new for-profit business model that will deliver a scalable, sustainable process to provide, distribute and administer vaccines to populations worldwide. Our goal is to have a recurrent, reliable way to obtain vaccines so we can continue to shrink the pool of the unvaccinated and determine when boosters are needed. Maintaining viable immunity levels through multiple vaccinations will continue to ward off severe consequences of a myriad of human and animal viruses and keep our economies open. PDTi is designed to meet this challenge, using a for-profit business model, to bring equitable access to vaccine for a broad population.
We also recognize that a critical component of a post-COVID-19 health system is biosimilar product creation. This new class of drugs have changed the healthcare industry by significantly improving the quality of human lives while also having the potential to be a lower-cost treatment option. PDTi’s Mission includes a strategy to help transform the usage of biosimilars to improve the human condition.
